Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2009 1
2010 6
2011 1
2012 5
2013 7
2014 23
2015 67
2016 129
2017 180
2018 184
2019 247
2020 347
2021 392
2022 392
2023 326
2024 158

Text availability

Article attribute

Article type

Publication date

Search Results

2,163 results

Results by year

Filters applied: . Clear all
Page 1
Sacubitril.
[No authors listed] [No authors listed] 2019 Feb 28. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2019 Feb 28. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 29999934 Free Books & Documents. Review.
Sacubitril is available in the United States only in combination with valsartan. Because no information is available on the use of sacubitril or valsartan during breastfeeding, an alternate drug may be preferred, especially while nursing a newborn or preterm infant. …
Sacubitril is available in the United States only in combination with valsartan. Because no information is available on the use of …
Renal protection in chronic heart failure: focus on sacubitril/valsartan.
Pontremoli R, Borghi C, Perrone Filardi P. Pontremoli R, et al. Eur Heart J Cardiovasc Pharmacother. 2021 Sep 21;7(5):445-452. doi: 10.1093/ehjcvp/pvab030. Eur Heart J Cardiovasc Pharmacother. 2021. PMID: 33822031 Free PMC article. Review.
However, data on the efficacy and tolerability of sacubitril/valsartan in patients with more advanced CKD are limited. This review discusses the evidence for the role of sacubitril/valsartan in providing additional renal benefit in patients with HFrEF. ...
However, data on the efficacy and tolerability of sacubitril/valsartan in patients with more advanced CKD are limited. This review di …
Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF.
Vaduganathan M, Mentz RJ, Claggett BL, Miao ZM, Kulac IJ, Ward JH, Hernandez AF, Morrow DA, Starling RC, Velazquez EJ, Williamson KM, Desai AS, Zieroth S, Lefkowitz M, McMurray JJV, Braunwald E, Solomon SD. Vaduganathan M, et al. Eur Heart J. 2023 Aug 14;44(31):2982-2993. doi: 10.1093/eurheartj/ehad344. Eur Heart J. 2023. PMID: 37210743 Free PMC article. Clinical Trial.
CONCLUSION: In pooled analyses of PARAGLIDE-HF and PARAGON-HF, sacubitril/valsartan reduced cardiovascular and renal events among patients with HF with mildly reduced or preserved ejection fraction. These data provide support for use of sacubitril/valsartan in patie …
CONCLUSION: In pooled analyses of PARAGLIDE-HF and PARAGON-HF, sacubitril/valsartan reduced cardiovascular and renal events among pat …
Network meta-analysis of sacubitril/valsartan for the treatment of essential hypertension.
Zhang Y, Zhao X, Huang H, Li M. Zhang Y, et al. Clin Res Cardiol. 2023 Jul;112(7):855-867. doi: 10.1007/s00392-022-02120-0. Epub 2022 Nov 3. Clin Res Cardiol. 2023. PMID: 36326841 Free PMC article. Review.
AIM: Sacubitril/valsartan has been demonstrated to reduce blood pressure in hypertensive patients, but the best dose remains unclear. ...Moreover, it is not clear that sacubitril/valsartan lowers blood pressure more than an angiotensin receptor blocker. ...
AIM: Sacubitril/valsartan has been demonstrated to reduce blood pressure in hypertensive patients, but the best dose remains unclear. …
Sacubitril/Valsartan Off-Label Uses for Heart Failure.
Kido K, Colvin BM, Szymanski TW, Guglin M. Kido K, et al. J Card Fail. 2022 Jul;28(7):1185-1201. doi: 10.1016/j.cardfail.2022.03.348. Epub 2022 Apr 9. J Card Fail. 2022. PMID: 35405341 Review.
Sacubitril/valsartan is an angiotensin receptor/neprilysin inhibitor that the Food and Drug Administration has indicated to reduce the risk of cardiovascular hospitalization and death in patients with left ventricular ejection fraction below normal and with no specified ej …
Sacubitril/valsartan is an angiotensin receptor/neprilysin inhibitor that the Food and Drug Administration has indicated to reduce th …
Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study.
Rakugi H, Kario K, Yamaguchi M, Sasajima T, Gotou H, Zhang J. Rakugi H, et al. Hypertens Res. 2022 May;45(5):824-833. doi: 10.1038/s41440-021-00819-7. Epub 2022 Jan 21. Hypertens Res. 2022. PMID: 35058583 Free PMC article. Clinical Trial.

Greater reductions in msSBP with sacubitril/valsartan 400 mg vs. olmesartan, as well as in msDBP and msPP with both doses of sacubitril/valsartan vs. olmesartan (P < 0.05 for all), were also observed. Patients treated with sacubitril/valsartan achieved an

…
Greater reductions in msSBP with sacubitril/valsartan 400 mg vs. olmesartan, as well as in msDBP and msPP with both doses of sacub …
Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With Pre-Heart Failure With Preserved Ejection Fraction: The PARABLE Randomized Clinical Trial.
Ledwidge M, Dodd JD, Ryan F, Sweeney C, McDonald K, Fox R, Shorten E, Zhou S, Watson C, Gallagher J, McVeigh N, Murphy DJ, McDonald K. Ledwidge M, et al. JAMA Cardiol. 2023 Apr 1;8(4):366-375. doi: 10.1001/jamacardio.2023.0065. JAMA Cardiol. 2023. PMID: 36884247 Free PMC article. Clinical Trial.
Major adverse cardiovascular events occurred in 6 patients (4.9%) assigned to sacubitril/valsartan and 17 (13.3%) assigned to receive valsartan (adjusted hazard ratio, 0.38; 95% CI, 0.17 to 0.89; adjusted P = .04). ...More work is needed to understand the observed increase …
Major adverse cardiovascular events occurred in 6 patients (4.9%) assigned to sacubitril/valsartan and 17 (13.3%) assigned to receive …
Sacubitril/valsartan: An antiarrhythmic drug?
Huang E, Bernard ML, Elise Hiltbold A, Khatib S, Polin GM, Rogers PA, Dominic P, Morin DP. Huang E, et al. J Cardiovasc Electrophysiol. 2022 Nov;33(11):2375-2381. doi: 10.1111/jce.15670. Epub 2022 Oct 2. J Cardiovasc Electrophysiol. 2022. PMID: 36069136 Review.
METHODS AND RESULTS: We reviewed and synthesized the available literature regarding sacubitril/valsartan and its effects on cardiac rhythm. ARNi has been shown to decrease cardiovascular mortality and hospitalization in patients with HF with reduced ejection fraction (HFrE …
METHODS AND RESULTS: We reviewed and synthesized the available literature regarding sacubitril/valsartan and its effects on cardiac r …
Sacubitril/valsartan: research progress of multi-channel therapy for cardiorenal syndrome.
Wang S, Wang Y, Deng Y, Zhang J, Jiang X, Yu J, Gan J, Zeng W, Guo M. Wang S, et al. Front Pharmacol. 2023 May 5;14:1167260. doi: 10.3389/fphar.2023.1167260. eCollection 2023. Front Pharmacol. 2023. PMID: 37214467 Free PMC article. Review.
Drugs only targeting the RAAS and NPs systems are not effective. Sacubitril/valsartan contains two agents (sacubitril and valsartan) that can regulate RAAS and NPs simultaneously. ...Therefore, based on RAAS and NPs as CRS biomarkers, this paper summarizes possible …
Drugs only targeting the RAAS and NPs systems are not effective. Sacubitril/valsartan contains two agents (sacubitril and vals …
Sacubitril/valsartan in heart failure: efficacy and safety in and outside clinical trials.
Abdin A, Schulz M, Riemer U, Hadëri B, Wachter R, Laufs U, Bauersachs J, Kindermann I, Vukadinović D, Böhm M. Abdin A, et al. ESC Heart Fail. 2022 Dec;9(6):3737-3750. doi: 10.1002/ehf2.14097. Epub 2022 Aug 3. ESC Heart Fail. 2022. PMID: 35921043 Free PMC article. Review.
Currently, the optimization of guideline-directed chronic HF therapy remains the mainstay to further improve quality of life, mortality, and HF hospitalizations for patients with HFrEF. The angiotensin receptor-neprilysin inhibitor sacubitril/valsartan (S/V) has an importa …
Currently, the optimization of guideline-directed chronic HF therapy remains the mainstay to further improve quality of life, mortality, and …
2,163 results

Searches related to "sacubitril"